Search
Omalizumab
go.drugbank.com/drugs/DB00043ApprovedInvestigationalBy binding to IgE and neutralizing it, omalizumab reduces free IgE levels and prevents IgE from binding to its receptors on immune cells. … [A39518] Omalizumab was first approved in the US in 2003 [A263507] and in Europe in 2005.
Products: Xolair 75mg Powder and Solvent for Solution for Injection, Xolair 150mg Powder and Solvent for Solution for InjectionSodium zirconium cyclosilicate
go.drugbank.com/drugs/DB14048ApprovedInvestigational[L2933] The treatment effect was maintained for up to 12 months.[L2933] … [L2933] Approval of the medication is supported by data from three double-blind, placebo-controlled trials and two open-label trials which showed that the onset of action was approximately 1.0 hour and
Categories: Drugs for Treatment of Hyperkalemia and Hyperphosphatemia, Compounds used in a research, industrial, or household settingProducts: LOKELMA POWDER FOR ORAL SUSPENSION 5G, LOKELMA POWDER FOR ORAL SUSPENSION 10GTrastuzumab
go.drugbank.com/drugs/DB00072ApprovedInvestigationalWhile Ogivri is the first biosimilar approved in the U.S. for the treatment of breast cancer or stomach cancer, it is the second biosimilar approved in the U.S. for the treatment of cancer. … In December 2017, FDA approved OGIVRI (trastuzumab-dkst) as a biosimilar to Herceptin (trastuzumab) for the treatment of patients with breast or metastatic stomach cancer (gastric or gastroesophageal junction
Products: Herzuma (trastuzumab) 150 mg Powder for Concentrate for Solution for Infusion, HERZUMA® 440MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSIONHydrogen peroxide
go.drugbank.com/drugs/DB11091ApprovedInvestigationalVet approvedDue to its potent and broad-spectrum antimicrobial actions, hydrogen peroxide is used in both liquid and gas form for preservative, disinfection and sterilization applications as an oxidative biocide [ … Hydrogen peroxide is also considered as a generally recognized as safe compound by the FDA [L2024]; it is used as an antimicrobial agent in starch and cheese products, and as an oxidizing and reducing
Mixtures: Orajel Antiseptic Rinse For All Mouth Sores, Orajel Antiseptic Rinse For All Mouth SoresCategories: Antiinfectives and Antiseptics for Local Oral Treatment, Compounds used in a research, industrial, or household settingBurosumab
go.drugbank.com/drugs/DB14012ApprovedInvestigationalMost children with XLH suffer from bowed or bent legs, short stature, bone pain and severe dental pain. … This is the first drug approved to treat adults and children ages 1 year and older with X-linked hypophosphatemia (XLH), which is a rare, inherited form of rickets.
Categories: Drugs for Treatment of Bone DiseasesProducts: CRYSVITA 10 MG SOLUTION FOR INJECTION, CRYSVITA 20 MG SOLUTION FOR INJECTIONInsulin glargine
go.drugbank.com/drugs/DB00047ApprovedInvestigationalInsulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. … Available as the brand name product Lantus, insulin glargine has a duration of action up to 24 hours allowing for once-daily dosing, typically at bedtime.
Mixtures: Soliqua SoloStar 100units/mL+33mcg/mL solution for injection in a pre-filled pen, SOLIQUA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100UNITS/ML + 50MCG/MLProducts: solution for Injection in vial 100 Units/ml, Glaritus 100 IU/mL Solution for injectionDurvalumab
go.drugbank.com/drugs/DB11714ApprovedInvestigational[L12624] It is additionally approved in Canada under the same name (Imfinzi) for similar indications, as well as the treatment of patients with locally advanced or metastatic urothelial carcinoma. … It was granted accelerated approval by the FDA in May 2017 [A192807] for the treatment of selected patients with locally advanced or metastatic urothelial carcinoma.
Products: IMFINZI CONCENTRATE FOR SOLUTION FOR INFUSION 50 MG/ML, IMFINZI CONCENTRATE FOR SOLUTION FOR INTRAVENOUS INFUSION 50 MG/MLParecoxib
go.drugbank.com/drugs/DB08439ApprovedInvestigationalA letter of non-approval for parecoxib was issued by the FDA in 2005. … It is approved through much of Europe for short term perioperative pain control much in the same way ketorolac (Toradol) is used in the United States.
Products: Dycox 40mg Powder for Solution for Injection, Dynastat Powder for Solution for Injection 40mgCanakinumab
go.drugbank.com/drugs/DB06168ApprovedInvestigationalCanakinumab binds to human IL-1β and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). … Clinical trials have established the administration of canakinumab every 2 weeks to be safe and effective, offering a considerable advantage over the existing treatment with the human IL-1 receptor antagonist
Products: ILARIS 150MG POWDER FOR SOLUTION FOR INJECTION, Ilaris Powder for Solution for Injection 150mg/vialAvelumab
go.drugbank.com/drugs/DB11945ApprovedInvestigational[A261496] On September 18 and December 18 of the same year, it was also granted approval by EMA [L48126] and Health Canada,[L48171] respectively. … [A261496] Avelumab was first approved by the FDA on March 23, 2017.
Products: BAVENCIO CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/10ML, BAVENCIO 200 mg/10mL concentrate for solution for infusion